Segment Information (Tables)

3 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Revenue by Reportable Segment

The following table presents revenue for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:

	Three Months Ended September 30
(in millions)	2013			2012
Pharmaceutical (1)	$	21,813		$	23,498
Medical	2,711			2,393
Total segment revenue	24,524			25,891
Corporate (2)	(1		)	(2		)
Total revenue	$	24,523		$	25,889

(1) The decrease in Pharmaceutical segment revenue is primarily due to the expiration of our pharmaceutical distribution contracts with Walgreen Co. ("Walgreens") on August 31, 2013 and Express Scripts, Inc. on September 30, 2012.

(2) Corporate revenue consists of the elimination of inter-segment revenue.

Segment Profit by Reportable Segment

The following table presents segment profit by reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:

	Three Months Ended September 30
(in millions)	2013			2012
Pharmaceutical	$	433		$	400
Medical	106			74
Total segment profit	539			474
Corporate	(68		)	(17		)
Total operating earnings	$	471		$	457

Assets by Reportable Segments

The following table presents total assets for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated balance sheets at the dates indicated below:

(in millions)	September 30, 2013		June 30, 2013
Pharmaceutical (1)	$	13,874	$	16,258
Medical	6,473		6,521
Corporate	3,469		3,040
Total assets	$	23,816	$	25,819

(1) The decrease in Pharmaceutical segment assets is primarily due to the decrease in trade receivables, net and inventories, net as a result of the expiration of our pharmaceutical distribution contract with Walgreens.